Autosomal dominant polycystic kidney disease (ADPKD) is a heterogeneous disease caused by mutations in PKD1 and PKD2. The genotype-phenotype correlations are not completely understood. We performed direct PCR-sequencing plus multiplex ligation-dependent probe amplification for PKD1 and PKD2 in 46 unrelated patients. Disease-causing mutations were identified in 30 (65%) patients: 23 (77%) patients have mutations in PKD1 and 7 (23%) have mutations in PKD2. Nonsense, splicing or frame-shifting mutations were found in 18 patients, exon duplication in 1 and missense mutations in 11 patients. Two likely PKD1 hypomorphic alleles (p.Arg2477His and p.Arg3439Trp) segregated with mild disease in a family. A total of 34 mutations were identified and 17 (50%) of which are novel. The median age at onset of dialysis was significantly earlier in patients with PKD1 mutations (52 years) than in patients with PKD2 mutations (65.5 years) and those with an undetermined genotype (67 years) by survival analysis (log-rank test, P ¼ 0.014). Patients carrying PKD1-truncating mutations have a trend toward earlier initiation of dialysis compared with carriers of non-truncating mutations (52 years vs 57 years, P ¼ 0.061). A family history of dialysis before 55 years was more common in PKD1 patients than in others (Po0.05). In conclusion, this study identified novel mutations in PKD1 and PKD2 and demonstrated the presence of PKD1 hypomorphic alleles in Taiwanese patients. Patients carrying PKD1 mutations, especially those with truncating mutations, could have a more rapidly progressive disease than others. These results might have implications for diagnosis and risk stratification in patients with ADPKD.
INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder resulting from mutations in PKD1 (MIM#601313) and PKD2 (MIM#173910) genes. 1 In clinically defined populations, mutations in PKD1 and PKD2 account for 85% and 15% of cases, respectively. 2 This slowly progressive disease is not only associated with multiple kidney cysts but also causes systemic manifestations, such as liver cysts and cerebral aneurysms. 3 The protein products of PKD1 and PKD2 are polycystin-1 (PC-1) and PC-2, respectively. These two proteins are critical for maintaining normal renal tubular structure during kidney development. [4] [5] [6] PC-1 and PC-2 have been found in primary cilia to act as a mechanosensor 7, 8 and between cells or at cell-matrix attachments to mediate cell adhesion. 9, 10 End-stage renal disease (ESRD) is expected in nearly 50% of ADPKD patients at the age of 60 years. 11 Patients with PKD1 mutations usually have an average age at onset of ESRD earlier than patients with PKD2 mutations (53.4 years vs 72.7 years). 12, 13 Both locus and allelic heterogeneity in the PKD genes may influence the rate of disease progression, 14, 15 but the genotype/ phenotype correlations are not entirely clear.
Molecular diagnostics for ADPKD has become available and increasingly important in recent years. 2 Traditional diagnostic approach is based on renal ultrasound that cannot exclude the disease in at-risk individuals until the age of 40 years, especially in families with mutations in PKD2. 16 PCR and direct sequencing analysis can provide direct evidence of PKD mutations, while multiplex ligation-dependent probe amplification (MLPA) may detect large deletion/duplication mutations that cannot be detected by direct sequencing. 17, 18 However, there are no mutation hot spots in PKD genes. 2 Furthermore, interpretation of the identified missense mutations can be challenging, because multiple sequence variants exist in PKD1 and PKD2. 19 Recent studies have demonstrated the existence of incompletely penetrant PKD1 mutations. [20] [21] [22] The combination of these hypomorphic PKD1 alleles may cause typicalto-severe cystic disease, whereas one such allele may cause unusually mild disease. 23 The Polycystic Kidney Mutation Database (PKDB; http://pkdb.mayo.edu) is a continually updated online reference describing all published PKD mutations and variants. 24, 25 A collection of more mutation data of PKD genes from different populations would allow better interpretation of the results of genetic testing.
Although PKD mutations from different countries have been reported, data in the Taiwanese population are still lacking. 19, 26 Here we report on our single-center experience of direct sequencing and MLPA for PKD1 and PKD2 in 46 unrelated Taiwanese patients with an ultrasound diagnosis of ADPKD. The specific purpose was to examine the characteristics of mutations in our cohort and their correlations to disease progression.
PATIENTS AND METHODS Patients
A total of 46 unrelated patients with a clinical diagnosis of ADPKD at the Chang Gung Memorial Hospital, Linkou, Taiwan were enrolled between October 2008 and May 2011. All participants signed written informed consent. Approval for this work had been obtained from the Institutional Review Board Committee at the Chang Gung Memorial Hospital. The study was conducted in adherence to the Declaration of Helsinki. The diagnosis of ADPKD was made according to the renal ultrasound criteria. 27 In the absence of a family history of ADPKD, bilateral renal enlargement and at least 10 cysts in each kidney were required for diagnosis. 28 Blood samples were obtained from these patients and their available families members. Control DNA was obtained from a database of healthy volunteers.
Clinical assessment
Patients were interviewed for family and medical histories. A family history of early dialysis (before the age of 55 years) and late dialysis (after the age of 65 years or no need for dialysis) due to ADPKD was recorded. 13 Clinical and laboratory data were obtained from medical records. An estimated glomerular filtration rate (eGFR) was calculated according to the Modification of Diet in Renal Disease study equation. 29 
Mutation analysis of PKD1 and PKD2
Genomic DNA was extracted from lymphocytes harvested from venous blood samples. Direct sequencing of exonic and flanking introgenic regions of all PKD1 and PKD2 exons was performed as previously published methods. 25, 30 For amplifying the duplicated part of PKD1 (exons 1-34), long-range PCR was first performed. Seven distinct long-range PCR fragments (exon 1, exons 2-7, exons 8-12, exons 13-15, exons 15-21, exons 22-28 and exons 29-34) were amplified using PKD1-specific primers. 25, 30 Exons 35-46 of PKD1 and exons 1-15 of PKD2 were amplified from genomic DNA according to previously described PCR primers and conditions. 30, 31 The PCR products were purified and sequenced on an ABI3730 autosequencer (Applied Biosystems, Foster City, CA, USA). The pathogenicity of missense variants were evaluated using SIFT, PolyPhen and GVGD prediction programs as described previously. 20 The 1000 Genomes Project data (http://browser.1000genomes.org), the Exome Sequencing Project (http://evs.gs.washington.edu/EVS) and the SingleNucleotide Polymorphism Database were checked for the reported sequence variants. The Human Splicing Finder software (http://www.umd.be/HSF/) was used to predict splicing signal. 32 PKDB (http://pkdb.mayo.edu) was consulted for the previously reported mutations. The recommendation of HGVS (Human Genome Variation Society) for mutation nomenclature was followed. Nucleotide changes were numbered according to the coding sequences of PKD1 (NM_001009944.2) and PKD2 (NM_000297.3).
MLPA
Screening for PKD1/PKD2 exon deletion/duplication was performed using MLPA according to the manufacturer's instructions. The MLPA kit (SALSA MLPA KIT P351-B1/P352-B1 PKD1-PKD2) was purchased from MRC-Holland (Amsterdam, The Netherlands). 33 It contains PKD1 probes for 37 of the 46 exons and 15 PKD2 probes covering all PKD2 exons. Data were analyzed using the Coffalyser MLPA analysis tool (MRC-Holland, Amsterdam, The Netherlands).
Real time quantitative PCR (Q-PCR)
MLPA revealed one family with significant copy number variation of probe for PKD1 exon 1. To validate the results of MLPA, a real-time Q-PCR was performed using Custom Taqman Copy Number Assays (Applied Biosystems, Carlsbad, CA, USA). A set of commercially designed primers against the binding site of MLPA PKD1 exon 1 probe was used (Assay ID: PKD1E1_CCS07DN). The reaction was performed in triplicate for each sample.
Statistical analysis
Continuous variables are expressed as mean ± s.d. and compared using oneway analysis of variance. Categorical variables were analyzed using the Fisher's exact or Chi-square test. Cumulative renal survival curves were generated by the Kaplan-Meier method and compared with the log-rank test. P-values o0.05 were considered statistically significant. All analyses were performed using the Graphpad Prism 5.1 (Graphpad, La Jolla, CA, USA).
RESULTS

Clinical characteristics and genotyping
We performed a complete mutational analysis using direct sequencing and MLPA analysis of PKD1 and PKD2 in 46 unrelated patients with the diagnosis of ADPKD by ultrasound. We found disease-causing mutations in 30 (65%) patients: 23 (77%) patients have PKD1 mutations and 7 (23%) have PKD2 mutations. The remaining 16 (35%) were categorized as undetermined genotype either because no mutations were detected or the identified variants were interpreted as nonpathogenic variants. Table 1 summarizes the clinical characteristics in the study cohort according to their genotypes. There were 24 male and 22 female patients. The mean age was 47.5 ± 13.0 years. ADPKD family history was reported in 35 (76%) patients. Family history of ADPKD with early dialysis (age p55 years) was found in 11 (24%) patients, whereas late dialysis (age 465 years) was reported in 8 (17%) patients. Hypertension was noted in 31 (67.4%) patients while gross hematuria, urinary tract infection and urolithiasis were found in 13 (28.3%), 16 (34.8%) and 19 (41.3%) patients, respectively. Subarachnoid hemorrhage was noted in 1 (2.2%) patient and two patients reported documented cerebral aneurysms. Mitral valve prolapse was noted in 1 (2.2%) patient. Extrarenal cysts in the liver, pancreas and spleen were detected in 29 (63%) patients. In patients with PKD1 mutations, the ages at recruitment tended to be younger than the other two groups (P ¼ 0.09). A family history of dialysis after 65 years was more frequent in patients with PKD2 mutations, whereas a family history of dialysis before 55 years was more frequent in patients with PKD1 mutations (Po0.05). Other clinical parameters and antihypertension medication use were not significantly different between genotypes.
The kidney sizes as estimated by ultrasound were not different between genotypes. However, patients with PKD1 mutations in our study tended to be younger than patients with PKD2 mutations, suggesting that kidney enlargement may occur earlier in PKD1 patients than in PKD2 patients.
Renal survival analysis
We then performed a Kaplan-Meier survival curve analysis to compare the age at onset of ESRD between different genotypes. As shown in Figure 1a , PKD1 patients (n ¼ 23) have a significantly lower renal survival curve than PKD2 patients (n ¼ 7) and patients with an undetermined genotype (n ¼ 16) (log-rank test, P ¼ 0.014). The median age of ESRD was 52 years in patients with PKD1 mutations (n ¼ 7, range 40-58 years), 65.5 years in patients with PKD2 mutations (n ¼ 2, range 64-67 years) and 67 years in patients with an undetermined genotype (n ¼ 6, range, 41-79 years). We then investigated whether the type of PKD1 mutation influenced the age at onset of ESRD. We found a trend of earlier initiation of dialysis in patients with PKD1-truncating mutations (n ¼ 14) compared with patients with PKD1 missense mutations (n ¼ 9) as shown in Figure 1b (log-rank test, P ¼ 0.061). The median age of ESRD in patients with and without PKD1-truncating mutations was 52 (n ¼ 5) and 57 (n ¼ 2) years, respectively.
Characteristics of mutations
Using direct PCR sequencing, we found 15 definite pathogenic mutations (12 in PKD1 and 3 in PKD2) in 17 (35%) probands (Tables 2 and 3) . Among these mutations, 9 (60%) were nonsense mutations, 5 (33%) were frame-shifting and 1 (7%) was splicing mutation. We identified two novel PKD2 missense mutations (p.Try392Asp and p.Ala389Val) predicted to be likely pathogenic (Table 3) . Fifteen PKD1 missense mutations, which were predicted to be likely pathogenic, were identified in nine patients (Table 4) . A deletion mutation in PKD1 intron 38 (c.IVS38-100_98del3) predicted to generate new splice sites was found in one patient who started maintenance dialysis at the age of 40 years (Table 4) . One patient (CG44) was found to have a PKD1-truncating mutation (p.Glu2810X) and four likely pathogenic missense mutations (Table 4) . She experienced right middle cerebral artery infarction at the age of 45 years and an aneurysm was found in the right cranial internal carotid artery by angiography. She had advanced chronic kidney disease (eGFR 15 ml per min per 1.73 m 2 ) at the age of 50 years. In total, we identified 119 different sequence variants of PKD1 and PKD2: 15 (13%) are definite pathogenic mutations, 17 (14%) are likely pathogenic mutation, 50 (42%) are likely non-pathogenic missense mutation and 37 (31%) are silent polymorphism. Novel
Large duplication mutation
To identify large deletion or duplication mutation that cannot be detected by direct sequencing, we then performed a copy number analysis using MLPA on all patients in this cohort. There were no multiple exon deletions found. Duplication of PKD1 exon 1 (relative peak ratio 1.66) was identified in a 47-year-old woman, and a similar result was found in her son (relative peak ratio: 1.58) (Figure 2a ). Repeated MLPA gave similar results. These results were further 
Hypomorphic alleles
In one family, the concurrence of PKD1 p.Arg2477His and p.Arg3439Trp variants segregated with the presence of polycystic kidney disease in two sisters (Figure 3a) . To our surprise, their parents and two other siblings, each of them carries PKD1 p.Arg3439Trp or p.Arg2477His, were negative for renal cysts. These results suggested that p.Arg3439Trp and p.Arg2477His could be hypomorphic alleles, as both were incompletely penetrant. PKD1 p.Arg2477His has been previously reported in a Han Chinese family as a pathogenic mutation, 34 but whether or not it coexisted with other missense mutations is not known. PKD1 p.Arg3439Trp is predicted to be highly likely pathogenic by computer programs, and its allele frequency in the Exome Sequencing Project was 1/ 12972 (Table 4) . Amino-acid multi-alignments demonstrate that the positions of mutations are highly conserved across species in p.Arg3439Trp and partially conserved in p.Arg2477His (Figure 3b ).
Undetermined genotype
There were 16 patients who had no PKD variants found or the identified sequence variants were interpreted as non-pathogenic. These patients tended to have a slower decline of renal function than the patients with PKD1 mutations (Figure 1a ). Other clinical characteristics were not significantly different in patients with an undetermined genotype compared with others (Table 1) .
DISCUSSION
We performed a comprehensive clinical and mutational analysis in a cohort of ADPKD patients. This is the first study to describe the characteristics of PKD1 and PKD2 mutations in Taiwan. Worldwide, there have been 1923 sequence variants for PKD1 and 241 for PKD2 as described in the PKDB. Among these variants, 929 of PKD1 and 167 of PKD2 are pathogenic mutations. In the current study, 50% (17/34) of mutations are novel and 50% (17/34) are recurrent mutations reported in the literature. The 17 novel mutations we found in the Taiwanese population would expand the spectrum of PKD mutations and contribute to the global references for genetic counseling of ADPKD patients. Among the 34 mutations we identified, only three mutations were present in more than one unrelated patient. This is consistent with the findings that no single mutation accounts for 42% of unrelated ADPKD patients in previous studies. 2, 35 Therefore, ADPKD patients who seek for the genetic diagnosis need to undergo a complete mutation analysis of PKD1 and PKD2 unless the causative mutations have been identified in other family members. Nevertheless, a recurrent mutation PKD2 p.R803X was found in three families in Taiwan and five families in other populations. 30, [36] [37] [38] [39] This frequent mutation could be related to its location in the CpG dinucleotide site that is susceptible to Novel PKD1 and PKD2 mutations M-Y Chang et al mutations, or it could be a founder mutation that derived from the common ancestor. 35 The frequency of large rearrangements reported in a large ADPKD cohort (n ¼ 202) was 4%. 17 In this study, we identified duplication of PKD1 exon 1 by MLPA and Q-PCR in 1 out of 46 cases (2%). A previous study has reported duplication of PKD1 IVS17 and exon 18 in one patient. 17 Overall, deletion and duplication mutations are rare in ADPKD patients, and MLPA can be reserved for those mutationnegative patients after direct PCR sequencing.
Knowing whether a family carries mutations in PKD1 or PKD2 may have prognostic value, because PKD2 patients typically develop ESRD two decades later than PKD1 patients. 26 Furthermore, the mutation type and location in PKD1 have been shown to influence renal survival in previous studies. 15 The position of the mutation in PKD1 has been shown to predict the occurrence of intracranial aneurysms. 40 In a recent report from 519 pedigrees in the Genkyst cohort, carriers of a PKD1-truncating mutation have a significantly earlier age at onset of ESRD than patients with a non-truncating mutation (55 years vs 67 years). 14 Our data support the notion that a more severe phenotype can be expected in PKD1 patients, especially in those with a PKD1-truncating mutation. Therefore, genetic testing for ADPKD patients would be helpful to clarify the disease status and provide prognostic information. 2 Robinson et al. 26 proposed that direct PKD2 mutation testing can be offered to identify the subgroup less likely to progress to ESRD. The prognostic information could be important for guiding the choice of potential treatments for ADPKD that might have side effects after long-term use. 28, 41 Hypomorphic PKD1 alleles are increasingly recognized in recent genotype-phenotype studies. [20] [21] [22] These missense variants have reduced PC-1 function and cause mild disease when present alone or severe disease when they occur simultaneously. In our cohort, we found two likely hypomorphic alleles, PKD1 p.Arg2477His and p.Arg3439Trp, which segregated with the disease in one family. To date, nine PKD1 hypomorphic alleles have been described in different populations as collated in PKDB. 21, 22 For example, a compound heterozygote for the PKD1 variants p.Arg3105Trp and p.Arg2765Cys caused multiple cysts in childhood, whereas another family member heterozygous for p.Arg2765Cys developed only one cyst. 20 Patients heterozygous for PKD1 p.Arg3277Cys had only few cysts, but those homozygous for p.Arg3277Cys developed multiple renal cysts and ESRD. 20 PKD1 p.Arg2220Trp and p.Arg3277Cyc in trans co-segregated with early-onset ADPKD, whereas no cysts were found in the heterozygous parents. 21 These findings support the concept of a critical cellular threshold of PCs in the pathogenesis of ADPKD. 22, 42 A valid functional study for these missense variants is still lacking. 22, 43 It is worth noting that a careful history taking for the age of ESRD in affected family members may provide a simple means of predicting the mutated gene in clinical practice. 13 Our results support the use of family history information as an aid in risk stratification. For those whose relatives have developed ESRD before the age of 50 years, the family history is highly suggestive of carrying a PKD1 mutation. 13, 26 For those whose affected members developed ESRD aged 470 years or continued to have sufficient renal function, the presence of a PKD2 mutation is highly likely. 13 In previous studies, disease-causing mutations were identified in approximately 64-90% of ADPKD patients by direct PCR sequencing. 35, 39 Another study using denaturing high-performance liquid chromatography found mutations in only 52% of ADPKD patients. 44 The possible causes of the relative low mutation detection rate in our study may include cohort size, methods of mutational analysis, sequencing technique, the presence of large deletion/duplication, deep intron sequence, mosaicism or mutations in other genes. In addition, some missense mutations that were incompletely penetrant could be interpreted as sequence variants. Furthermore, patients without a family history of ADPKD were included in our study. It seems that definite pathogenic mutations are found more frequently in patients with a positive family history of ADPKD than in those without. 2, 35 Several potential limitations of this study merit consideration. First, we only screened for PKD1 and PKD2 mutations and therefore cannot exclude the existence of other mutations such as HNF1b, PRKCSH, SEC63 or PKHD1 that may contribute to the cystic phenotype. 2 Second, the expensiveness of exon by exon DNA sequencing precludes us from recruiting more cases. Relatively small sample size may limit the ability to detect a small phenotypic difference between genotypes. Nevertheless, we were still able to detect phenotype differences in our study cohort. Finally, the likely pathogenic mutations identified in our study need to be confirmed in future studies involving more ADPKD families.
As potential therapies for ADPKD are being developed, molecular testing will likely become increasingly important. 2, 28 Another important indication is to determine the disease status of potential living related donors with equivocal imaging findings. 19, 45 A recent study has shown great promise of next-generation sequencing for genetic PKD diagnostics, because the time and effort needed to detect pathogenic mutations are markedly reduced. 46 Therefore, more efficient and low-cost genetic testing can be expected in the next decade, with the advance of DNA sequencing technique. 35, 46 In addition to genetic testing, a simple family history enquiry for the age of hemodialysis may yield prognostic information by estimating PKD1 (early dialysis) and PKD2 (late dialysis) genotypes. 13 Many clinical trials of different mechanism-based drug treatment for ADPKD are currently undergoing. 47 It would be interesting to know whether patients with different PKD mutations may respond differently to these novel treatments.
CONCLUSIONS
We presented the first complete clinical and mutational analysis of PKD1/PKD2 in Taiwanese patients with ADPKD. We identified 17 novel mutations of PKD1 and PKD2 and demonstrated the presence of PKD1 hypomorphic alleles. Patients carrying PKD1 mutations, especially those with truncating mutations, could have a more rapidly progressive disease than others. These results might have implications for diagnosis and risk stratification in patients with ADPKD.
